Scilex Holding Company — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter report; quarterly financial results are not provided in the supplied text. Scilex completed its business combination with Vickers on November 10, 2022, accounted for as a reverse recapitalization.
Business context
Scilex is a commercial-stage pain-management company focused on non-opioid products. FY2022 product revenue came solely from U.S. sales of ZTlido, an FDA-approved lidocaine topical system for postherpetic neuralgia. GLOPERBA, an FDA-approved gout prophylaxis product, was licensed in 2022 but had not yet launched. The pipeline includes SEMDEXA (SP-102) for sciatica, SP-103 for acute lower-back pain, and SP-104 for fibromyalgia.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Net revenue | $38.0 | $31.3 | Up 21.4%; increased ZTlido sales volume was partly offset by higher rebates. |
| Cost of revenue | $10.8 | $3.6 | Higher product volume, $4.5 million of royalty expense beginning in Q2, and other items. |
| Gross profit / margin | $27.2 / 71.6% | $27.7 / 88.4% | Gross profit was nearly flat despite revenue growth; margin contracted substantially. |
| Research and development | $9.1 | $9.2 | Lower SP-102 spending was largely offset by SP-103, SP-104 and GLOPERBA costs. |
| Selling, general and administrative | $64.9 | $50.6 | Up $14.3 million, including higher patent-litigation, consulting, travel and D&O insurance costs. |
| Operating loss | $(50.6) | $(35.8) | Loss widened as operating expenses grew. |
| Net loss | $(23.4) | $(88.4) | Improved mainly because of debt-extinguishment and derivative-liability gains, not operating improvement. |
| Net loss per share | $(0.17) | $(0.67) | Basic and diluted. |
| Cash used in operating activities | $(21.3) | $(28.7) | Cash burn continued; FY2022 working-capital movements included a large increase in accrued rebates and fees. |
| Cash and cash equivalents at year-end | $2.2 | $4.3 | Low cash balance relative to operating needs. |
At December 31, 2022, current assets were $29.6 million and current liabilities were $44.8 million, yielding negative working capital of approximately $15.2 million. Reported debt was zero after repayment of the Scilex Pharma Notes and conversion of related-party indebtedness into equity; $3.7 million of deferred GLOPERBA consideration remained. Total liabilities were $50.3 million, including $1.2 million of derivative liabilities. Total assets were $86.5 million and stockholders’ equity was $36.2 million.
Material changes and notable items
- ZTlido net revenue rose to $38.0 million. The company reported prescription growth of more than 50% and approximately 11.4% market share in covered U.S. territories at year-end.
- Gross-to-net deductions increased: accrued rebates and fees were $30.9 million at year-end, versus $7.4 million in 2021. Four customers each generated at least 10% of FY2022 revenue; together they represented 83% of revenue and 90% of year-end accounts receivable.
- Scilex extinguished its senior secured notes in September 2022, with $28.0 million of principal forgiven and a reported $28.6 million debt-extinguishment gain. It also recorded an $8.3 million derivative-liability gain. These non-operating items materially reduced the reported net loss.
- The November 2022 business combination provided approximately $3.4 million of net proceeds. Approximately $290.6 million of related-party debt and payables was converted into preferred and common equity. Sorrento remained the controlling stockholder and received Series A preferred shares with senior liquidation rights and governance protections.
- Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern. The auditor’s report includes a going-concern explanatory paragraph.
- Disclosure controls were deemed ineffective, and a material weakness in internal control over financial reporting remained unremediated at year-end. It involved revenue, business-combination, debt and derivative-liability accounting; management cited insufficient accounting resources and technical expertise.
Outlook, risks and contingencies
- Management expects continued losses and additional funding needs. It stated that cash, expected product revenue and available financing sources may be insufficient to fund operations for at least the next 12 months. No quantified revenue, earnings or cash-flow guidance is provided.
- Management planned to commercialize GLOPERBA in 2023 and expected to begin SP-104 Phase 2 studies in 2023. SP-103 Phase 2 began in Q2 2022. The completed SEMDEXA Phase 3 trial met its primary and key secondary endpoints, but the FDA could require additional studies before an NDA submission or approval.
- In February 2023, Scilex acquired U.S. and Canadian commercialization rights to ELYXYB, an FDA-approved migraine treatment, with plans to commercialize it in 2023. The transaction involved assumed royalty and milestone obligations; the filing does not state a cash purchase price.
- Scilex entered standby equity purchase agreements with Yorkville and B. Riley, each permitting up to $500 million of stock sales subject to conditions. The agreements are potential financing sources, not committed cash proceeds. Through March 3, 2023, reported net proceeds were approximately $0.6 million from Yorkville and $1.0 million from B. Riley.
- Key supply risks include dependence on Oishi and Itochu for ZTlido and SP-103, and Genzyme’s notice that its sodium-hyaluronate supply agreement for SEMDEXA will end effective May 31, 2024. Alternative suppliers are being pursued. The Oishi/Itochu agreements also give the developers termination rights if product net profits remain at or below 5% of net sales for four or more consecutive quarters; the company reported that this condition applied and the rights had not been exercised.
- Contingent obligations include up to $280 million tied to SEMDEXA regulatory and sales milestones, up to $13 million plus royalties and minimum royalties for GLOPERBA, and SP-104 milestone and royalty obligations. These are contingent, not current funded debt.
- Apotex challenged ZTlido patents in connection with a generic application. A 30-month stay was expected to prevent launch at least until November 11, 2024; the litigation outcome is uncertain. Other disclosed proceedings include Scilex’s advertising lawsuit against OTC lidocaine manufacturers and its former-employee litigation.
- Sorrento filed for Chapter 11 protection on February 13, 2023; Scilex is not a debtor in that case. Scilex disclosed a $1.8 million receivable from Sorrento, which the financial-statement note says was fully reserved. The filing’s descriptions differ on collectability, so the status should be checked against subsequent disclosures.
Most important facts for investors to verify
- Whether Scilex can secure sufficient financing and improve liquidity without excessive dilution; verify subsequent cash balances, equity-line usage and cash runway.
- Whether ZTlido growth translates into stronger net revenue and gross margin, given the increase in rebates, accrued rebates and royalty costs.
- Whether internal-control remediation is completed and whether future filings report reliable controls and financial estimates.
- Regulatory progress for SEMDEXA, SP-103 and SP-104, including FDA requirements, timelines, trial funding and the SEMDEXA excipient supply transition before May 2024.
- Launch execution, sales, reimbursement and contribution economics for GLOPERBA and ELYXYB, including associated royalties and minimum payments.
- Effects of Sorrento’s bankruptcy, its control and preferred-stock rights, and any impact on shared services, related-party balances or Scilex’s governance.
- Developments in the Apotex patent case and the potential timing and commercial impact of generic ZTlido competition.